86990-52-5Relevant academic research and scientific papers
SPIROCYCLIC TETRAHYDROQUINAZOLINES
-
, (2021/07/17)
Provided are compounds represented by Formula I, wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and (aa) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula (I) are KRAS inhibitors and are thus useful to treat cancer and other diseases.
Spirocyclic tetrahydroquinazolines
-
, (2021/07/11)
The invention discloses spirocyclic tetrahydroquinazolines , and particularly provide compounds represented by Formula I shown in the specification, and pharmaceutically acceptable salts and solvates thereof. In the formula, R3, A, A1, A2, A3, E, E1, E2, L, Q, Z and a structure shown in the specification are as defined in the specification,. The compounds of formula I are KRAS inhibitors and are therefore useful in the treatment of cancer and other diseases.
KRAS G12C INHIBITORS
-
, (2020/07/25)
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
UREIDOALLYLATION OF DOUBLE BONDS
Webb II, Robert R.,Danishefsky, Samuel
, p. 1357 - 1360 (2007/10/02)
Intramolecular ureidoselenation of double bonds followed by allylative de-selenylation accomplishes a net ureidoallylation.
